RESULTS
We identified 53,719 Medicare primary patients who underwent transplantation from January 2000 to September 2006. Within this cohort, 32,179 recipients were whites (59.9%) and 15,547 were AFs (28.9%). There were 719 patients (1.3%) who had Medicare claims for PTLD. The overall incidence rate of PTLD was 7.4 cases per 1000 person-years at risk (PYAR), 95% confidence interval (CI) 6.9 -7.9. For AFs, the incidence rate was 5.8 cases per 1000 PYAR (95% CI 5.1-6.6) and for non-AFs, 8.1 cases per 1000 PYAR (95% CI 7.5-8.6). Factors associated with PTLD on unadjusted analysis are shown in Table 1 . AF recipients had a significantly lower incidence of PTLD compared with non-AFs. When non-AF race was assessed separately as Native American, white, Asian, and Hispanic ethnicity, AF recipients had a significantly lower risk of PTLD compared with all other races, although for Native Americans this was not statistically significant. AF patients had a significantly higher incidence of acute rejection within 1 year posttransplant when compared with non-AFs (9.3% vs. 7.6%, PϽ0.001). There was a higher prevalent rate of EBV IgG seropositivity among AF when compared with non-AF recipients at the time of transplant, regardless of age (66.0% vs. 53.3%, PϽ0.001, for recipients Յ18 years and 88.9% vs. 86.3%, PϽ0.001, for recipients Ͼ18 years). Among the 166 AF recipients who developed PTLD, there was a higher proportion of individuals with positive EBV IgG in comparison to those who were non-AFs (51.8% vs. 46.5%, Pϭ0.01). A lower percentage of AF recipients with PTLD were seronegative in comparison to those who were non-AFs (7.8% vs. 15 .7%, Pϭ0.01). Missing data for EBV serology in patients with PTLD were not skewed toward a particular race (40.4% AF vs. 37.8% non-AF, Pϭ0.55).
Patients with PTLD were more likely to have a history of pretransplant malignancy than those without PTLD. Expanded criteria donor kidneys, delayed graft function, human leukocyte antigen mismatches, and peak panel reactive antibody more than 20% were not associated with an increased risk of PTLD. There was no association of cytomegalovirus, hepatitis C virus, and human immunodeficiency virus serostatus and the development of PTLD. None of the induction agents (thymoglobulin, alemtuzumab, rituximab, basiliximab, and daclizumab) was associated with PTLD. However, in unadjusted analysis, tacrolimus and sirolimus use at initial discharge posttransplant were associated with an increased risk of PTLD. There were a total of 131 patients on everolimus, none of whom developed PTLD; however, the incidence of PTLD associated with everolimus was not significant compared with patients on other agents (Pϭ0.47). Patients who developed acute rejection within the first 12 months posttransplant were associated with a higher risk of PTLD. Table 2 summarizes multivariate analyses of risk factors for the development of PTLD. AF recipients had a lower risk of developing PTLD. Also, recipient seronegative EBV IgG status was significantly associated with PTLD. Furthermore, race (AF vs. non-AF) significantly interacted with EBV IgG status for the outcome of PTLD. Therefore, in contrast to the AF population, recipient EBV serostatus was significantly associated with PTLD among non-AFs such that seronegative patients were at an increased risk (Figs. 1 and 2). Donor positive and recipient negative pairs were not significantly associated with PTLD. However, this analysis was limited to living donor-recipient pairing because data for deceased donors were not available during the study period. Other statistically significant risk factors included EBV-positive donors, age younger than 18 years, history of pretransplant malignancy, and rejection within 12 months. Of all the analyzed immunosuppressive medications, only de novo sirolimus was shown to be an independent risk factor for PTLD. There were no significant interactions between sirolimus use and other variables, notably race. However, there was a significant interaction between maintenance use of sirolimus and EBV IgG serostatus. As shown in Figure 3 , in analysis limited to recipients who were EBV IgG negative, sirolimus use was significantly associated with PTLD. However, in recipients who were EBV IgG positive, sirolimus was not significantly associated with PTLD (Pϭ0.18). In a separate multivariate analysis, there was no significant association between alemtuzumab induction (AHR 1.31, CI 0.90 -1.89, Pϭ0.16) and rituximab induction (AHR 1.12, CI 0.28 -4.40, Pϭ0.87) with the risk of PTLD.
Development of PTLD in the recipients was shown to be associated with a lower patient survival rate (AHR 3.84, CI 3.27-4.50, PϽ0.001), although primarily limited to the first 2 years after transplant. The mortality risk associated with PTLD did not differ significantly by race (Fig. 4) .
DISCUSSION
This analysis revealed a cumulative incidence of lymphoproliferative disorders of 1.3% at 3 years after transplant, within the range of 1% to 4.5% reported in multiple series. It is also similar to an incidence of 1.4% among Medicare kidney recipients who underwent transplantation from 1996 to 2000 in our prior analysis of the USRDS database (9) .
We found that non-AF patients, EBV-negative recipients, de novo sirolimus treatment, recipient history of pretransplant malignancy, and rejection within the first year of transplantation were associated with an increased risk of PTLD. Regarding race, the lower risk associated with AF recipients may be related to a higher prevalence of EBV seropositivity, as demonstrated in this study. Therefore, AFs develop a higher rate of EBV immunity at a young age. How- ever, AF race remained significant in multivariate analyses, even after adjusting for recipient EBV seronegativity. The question therefore arises whether there is a difference between the intensity of immunosuppression delivered to a white patient versus an AF patient, when both are given the same dosage of immunosuppressive drugs. We speculate that for the pharmacologically equivalent degree of immunosuppressant medications prescribed, AF patients may still be underimmunosuppressed compared with whites. This might explain why they have higher acute rejection rates (14) but less PTLD. Prior data already demonstrated altered genetic metabolism/lower absorption, increased immunoactive cytokines (15) and higher nonadherence in AF patients (16) , all of which could account for lower net immunologic effects.
Recipient EBV-seronegative status was significantly associated with PTLD. In particular, EBV-seronegative status in recipients predicts a higher risk for PTLD only in the non-AF population (Fig. 1) ; EBV serostatus was not associated with PTLD among AFs (Fig. 2) . Opelz et al. (7) have also demonstrated that negative EBV serostatus in the recipients was strongly associated with an increased risk of PTLD in their analysis of the Collaborative Transplant Study database. This finding is consistent with our results, as approximately 90% of the Collaborative Transplant Study cohort is white.
We did not detect any significant association between various induction and maintenance agents with PTLD, except for sirolimus. It has been speculated that the intensity of immunosuppression, rather than any particular agent, is the main determining factor of cancer risk (17) . However, in this study, de novo sirolimus use was associated with an increased risk of PTLD, which is an unexpected finding given the wellestablished antitumor activity of mammalian target of rapamycin inhibitors. Sirolimus inhibits the growth of solid tumors established from EBV-infected B-cell lines in a xenogeneic mouse model of PTLD (18) . A potential explanation for our findings is that patients with established PTLD are more likely to be managed with sirolimus, although the pres- ent analysis evaluated the use of sirolimus started upon discharge from the initial transplant hospitalization. In an analysis of 59,560 first kidney transplants using the OPTN/ United Network for Organ Sharing database, Kirk et al. (19) noted the same higher risk with de novo sirolimus (relative riskϭ2.05, PϽ0.0001). Thus, another possible explanation is that sirolimus use early may potentiate the immunosuppression enough to increase the risk of PTLD. Unlike cyclosporine, sirolimus in conjunction with costimulation blockade induces permanent graft acceptance in animal models (20) . We speculate that sirolimus could then lead to tolerance toward EBV if used de novo. Based on the current data, it is becoming more apparent that sirolimus does not provide any inherent protection against PTLD and may in fact increase the risk of PTLD. In particular, the higher risk associated with maintenance sirolimus is limited to EBV IgG-negative recipients. The clinical implication is that sirolimus should probably be avoided in EBV IgG-negative recipients, especially in those who are already at higher risk for PTLD. Whether everolimus has similar effects on PTLD is unknown.
Limitations specific to the USRDS database have been described elsewhere (21) . Our utilization of select International Classification of Diseases-9th Revision (ICD-9) diagnosis codes for lymphoproliferative diseases may have underestimated the true incidence of PTLD. The USRDS does not contain complete information for EBV serostatus, which limits stronger conclusions regarding the effect of EBV serostatus on the development of PTLD. The data on immunosuppressive medications were limited to the time at hospital discharge and follow-up, thus we cannot be certain of the particular regimens that were used at the time of diagnosis of PTLD. Associations between immunosuppressive agents and PTLD were nonrandomized and may be influenced by unmeasured confounders.
Racial disparities in renal transplantation outcomes have been well documented in the transplant literature, which are a matter of much concern and are a serious public health issue. Basic research and outcome studies have shown that these differences are due to multiple factors: immunologic hyperresponsiveness, lower socioeconomic status, poor adherence with medications and follow-up, and longer waiting time (22) . Despite both immunological and nonimmunological factors that favor whites, we have shown that AF recipients of kidney transplantation were at lower risk for PTLD, irrespective of the recipient EBV IgG serostatus.
Furthermore, de novo sirolimus therapy was associated with an increased risk of PTLD in EBV IgG-negative recipients, regardless of race. Therefore, EBV-negative recipients who are whites or receive sirolimus should be closely monitored for development of PTLD.
MATERIALS AND METHODS

Databases
This study used the USRDS database, which incorporates extensive baseline and follow-up demographic and clinical data on all patients accessing the Medicare end-stage renal disease program in the United States. The variables within the USRDS standard analysis files, as well as data collection methods and validation studies, are published and listed at the USRDS website, under "Researcher's Guide to the USRDS Database." Files used were as previously reported (23) . Unique demographics of patients with valid Medicare claims data have been described previously (24) . We used a cohort consisting of patients who underwent a first kidney transplant between January 1, 2000, and September 29, 2006.
Outcome Variables
The outcome variables were based on Institutional and Physician Supplier claims reported to Medicare for the time period between January 3, 2000, and December 31, 2007. Claims were identified by the ICD-9 diagnosis codes. The outcome variables were non-Hodgkin's lymphomas (ICD-9 codes 200x and 202x) and lymphoid leukemias (ICD-9 codes 204x). We assessed the first Medicare claim for PTLD after renal transplantation for a given individual who received a kidney transplant during the predefined period, requiring two outpatient codes or one inpatient code for a diagnosis of PTLD.
Independent Variables
Patient characteristics were those at the date of transplant, with the exception of data from the Centers for Medicare and Medicaid Services Form 2728, which includes demographic and comorbidity data obtained at the first treatment for end-stage renal disease, whether dialysis or transplant. Associations between patient factors and Medicare claims for risk of event were examined by unadjusted analysis, and afterward were adjusted for variables to include recipient age, race, gender, pretransplant malignancy, deceased donors, expanded criteria donor kidneys, delayed graft function, peak panel reactive antibody more than 20%, EBV, cytomegalovirus, human immunodeficiency virus serostatus, acute rejection during the first year after transplantation, and induction and maintenance agents at discharge.
Survival Times
The time to event (for diagnosis of PTLD) was defined as the time from renal transplant to the date of claim for PTLD, with patients censored for death, loss of follow-up, 3 years after the date of transplant as Medicare coverage ends 3 years after kidney transplantation, or end of the study period (December 31, 2007).
Statistical Analysis
Analyses were performed using SPSS 17.0 TM (SPSS, Inc., Chicago, IL) and Stata 11.1 (College Station, TX). Files were converted to SPSS files using DBMS/Copy (Conceptual Software, Houston, TX). Unadjusted analyses were performed with chi-square testing for categorical variables (Fisher's exact test used for violations of Cochran's assumptions, i.e., less than five observations in a category) and Student's t test for continuous variables (Mann-Whitney test used for nonnormally distributed variables); PϽ0.05 was considered statistically significant. Variables with P less than 0.10 in unadjusted analysis were entered into a multivariate analysis as covariates. Cox regression was used to model factors associated with event times controlling for covariates listed above. Kaplan-Meier analyses were used to construct survival plots of event times after renal transplantation. The Wilcoxon test was used for significance testing.
